Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Eli Lilly (LLY) PT Raised to $1,001 at BMO Capital
April 30, 2024 4:50 PM EDTBMO Capital analyst Evan David Seigerman raised the price target on Eli Lilly (NYSE: LLY) to $1,001.00 (from $900.00) while maintaining a Outperform rating.
The analyst comments "A high-quality earnings miss is one that 1) characterizes unprecedented demand; 2) justifies performance miss with supply constraints; 3) highlights efforts... More
Eli Lilly (LLY) PT Raised to $885 at Cantor Fitzgerald
April 30, 2024 2:01 PM EDTCantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to $885.00 (from $815.00) while maintaining a Overweight rating.
The analyst comments "For 1Q24, US Zepbound revenue was $517MM vs. $363MM for FactSet. Zepbound is already annualizing at over... More
Eli Lilly (LLY) stock climbs on gross margin beat, raised 2024 revenue outlook
April 30, 2024 6:59 AM EDT(Updated - April 30, 2024 10:00 AM EDT)
Eli Lilly & Co. (NYSE: LLY) saw its shares jump over 7% at the open on Tuesday after the pharmaceutical giant reported better-than-expected earnings and gross margin for the fiscal Q1 2024.
Specifically, Eli Lilly posted earnings per share (EPS) of $2.58, beating the analyst expectations of $2.48. However, the company's revenue for the quarter was $8.77 billion, falling short of the consensus estimate of $8.94 billion.
Importantly, the company's gross margin improved significantly, reaching 80.9% compared to 76.6% in the same period last year... More
